Antibody responses to SARS-CoV-2 can be detected in most infected individuals 10–15 d
after the onset of COVID-19 symptoms. However, due to the recent emergence of SARS-CoV-…

The HIV envelope (Env) protein gp120 is protected from antibody recognition by a dense
glycan shield. However, several of the recently identified PGT broadly neutralizing antibodies …

Improved understanding and management of COVID-19, a potentially life-threatening disease,
could greatly reduce the threat posed by its etiologic agent, SARS-CoV-2. Toward this end…

The frequency of, and risk factors for, long COVID are unclear among community-based
individuals with a history of COVID-19. To elucidate the burden and possible causes of long …

Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines show
protective efficacy, which is most likely mediated by neutralizing antibodies recognizing the viral …

Despite extensive studies into severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
the effect of maternal infection on the neonate is unclear. To investigate this, we …

The coronaviral spike is the dominant viral antigen and the target of neutralizing antibodies.
We show that SARS-CoV-2 spike binds biliverdin and bilirubin, the tetrapyrrole products of …

Broadly neutralizing antibodies against highly variable viral pathogens are much sought
after to treat or protect against global circulating viruses. Here we probed the neutralizing …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike is the target for
neutralizing antibodies elicited following both infection and vaccination. While extensive research …

Background The efficacy and safety profiles of vaccines against SARS-CoV-2 in patients with
cancer is unknown. We aimed to assess the safety and immunogenicity of the BNT162b2 (…